Reported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis

Cue Biopharma's CUE-221 achieved a 60% complete resolution of hives in a Phase 2 study for chronic spontaneous urticaria, compared to 24% for omalizumab (XOLAIR) in a post hoc analysis. The primary and key secondary endpoints were met with high statistical significance, and CUE-221 exhibited a favorable safety profile. This suggests a potentially different mechanism of action compared to existing treatments.